Physician profile
William C Anderson
NPI 1992961577
$53,438.49
in general payments reported to CMS, 2019-2025
10 companies · $15K in 2025
The $15K reported for 2025 was more than what 89% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,207 · 2021: $3,083 · 2022: $12K · 2023: $15K · 2024: $1,457 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Grant: $3,000 · Travel and Lodging: $1,389 · Honoraria: $1,220 · Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,648.50 |
| Grant | $3,000.00 |
| Travel and Lodging | $1,389.34 |
| Honoraria | $1,220.00 |
| Food and Beverage | $1,201.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $37,753.51 | 2021-2025 | |
| Glaxosmithkline, LLC. | $7,277.12 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $5,175.00 | 2021-2023 | Dupixent |
| Genentech USA, INC. | $1,551.34 | 2022 | |
| Alk-Abello, INC | $1,371.92 | 2025 | |
| Boston Scientific Corporation | $143.09 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $119.85 | 2022 | |
| Circassia INC. | $32.33 | 2023 | Niox |
| Amgen INC. | $14.33 | 2024 | Tezspire |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.